A 50-year-old with severe obesity (BMI 39) and T2D on metformin asks about weight-lowering pharmacotherapy with cardiometabolic benefit. Which aligns ...

Question

A 50-year-old with severe obesity (BMI 39) and T2D on metformin asks about weight-lowering pharmacotherapy with cardiometabolic benefit. Which aligns with guideline direction?

Accepted Answer

Consider GLP-1 receptor agonist or dual GIP/GLP-1 agent if available, with lifestyle therapy

Answer

Start orlistat as first-line for all

Answer

Use phentermine long-term monotherapy

Answer

Use SGLT2 inhibitor only for weight loss

Answer

Avoid pharmacotherapy if BMI

us-usmle-step-2 MCQ (SBA): Obesity Management

A 50-year-old with severe obesity (BMI 39) and T2D on metformin asks about weight-lowering pharmacotherapy with cardiometabolic benefit. Which aligns with guideline direction?